This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards-JenaValve injunction would serve public interest most, US judge says

By Wesley Brown ( January 23, 2026, 22:43 GMT | Insight) -- Despite arguments from Edwards Lifesciences and JenaValve that their merger is in the interest of American patients, US judge Rudolph Contreras sided with the US Federal Trade Commission that the companies competing separately would be the best way forward. In a newly released memorandum opinion, the court said it believes the “risk is low that an independent JenaValve would be unable to obtain FDA approval and commercialize Trilogy."Despite arguments from Edwards Lifesciences and JenaValve that their merger is in the interest of American patients, US District Judge Rudolph Contreras sided with the US Federal Trade Commission that the companies competing separately would be the best way forward....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login